Literature DB >> 30769255

A case of neuromyelitis optica spectrum disorder following seasonal influenza vaccination.

Jeong Hee Cho1, Yoonseon Park2, Naeun Woo3.   

Abstract

There have been reports of central nervous systemic inflammatory disease associated with vaccination. We describe a female patient who developed longitudinally extensive transverse myelitis following seasonal influenza vaccination. A 38-year-old woman had severe neck and back pain with urinary retention. She received influenza vaccine 3 days before symptom onset. Examination revealed mild quadriparesis with diffuse hyperreflexia. Magnetic resonance imaging (MRI) of the spine showed a T2 hyperintense lesion with gadolinium enhancement in the spinal cord extending from the cervicomedullary junction to the level of T10. Brain MRI revealed no specific finding for demyelinating lesions. Cerebrospinal fluid had a white blood cell count of 60/L (mononuclear cells 95%) with a protein concentration of 78.2 mg/dL and the blood serum was positive for anti-aquaporin-4 antibodies. She was treated with high-dose methylprednisolone for 5 days followed by tapering of prednisolone. Symptoms improved significantly after treatment. We report a case of neuromyelitis optica spectrum disorder following seasonal influenza vaccination. Neuromyelitis optica spectrum disorder may have been triggered by the recent influenza vaccination, although a pathogenic link has not been established.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Aquaporin 4; Influenza; Myelitis; Neuromyelitis optica; Vaccination

Mesh:

Substances:

Year:  2019        PMID: 30769255     DOI: 10.1016/j.msard.2019.01.052

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  1 in total

1.  A Case With New-Onset Neuromyelitis Optica Spectrum Disorder Following COVID-19 mRNA BNT162b2 Vaccination.

Authors:  Ilay Caliskan; Eser Bulus; Nazire Afsar; Ayse Altintas
Journal:  Neurologist       Date:  2022-05-01       Impact factor: 1.524

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.